Boehringer Ingelheim Sustainability Profile
Boehringer Ingelheim, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including treatments for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s dedication to research and development has led to significant milestones, positioning it among the top pharmaceutical firms worldwide. Notable achievements include a robust pipeline of novel therapies and a strong market presence in Europe, North America, and Asia. Boehringer Ingelheim continues to enhance its reputation through its unique approach to healthcare solutions, prioritising patient needs and sustainable practices.
DitchCarbon Score
How does Boehringer Ingelheim's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim's score of 28 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim's reported carbon emissions
In 2023, Boehringer Ingelheim reported total carbon emissions of approximately 361,000,000 kg CO2e, comprising 295,000,000 kg CO2e from Scope 1 and 66,000,000 kg CO2e from Scope 2. The company has set ambitious targets to reduce its greenhouse gas emissions, committing to a 58.9% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2019 baseline. Additionally, Boehringer Ingelheim aims for a 27.5% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, capital goods, and other related activities, within the same timeframe. In 2022, the company reported total emissions of approximately 4,239,000,000 kg CO2e for Scope 3, alongside 280,000,000 kg CO2e for Scope 1 and 71,000,000 kg CO2e for Scope 2. The emissions data is cascaded from its parent company, Boehringer Ingelheim GmbH, reflecting the organisation's commitment to sustainability and climate action within the pharmaceutical sector. Boehringer Ingelheim's targets align with the Science Based Targets initiative (SBTi), ensuring that their reduction goals are consistent with the global aim to limit temperature rise to 1.5°C. The company has not yet committed to a net-zero target but continues to enhance its sustainability efforts through various initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 289,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 273,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,801,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is Boehringer Ingelheim's Industry?
How Carbon Intensive is Boehringer Ingelheim's Location?
Boehringer Ingelheim's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boehringer Ingelheim has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
